A federal appeals court has mandated a return to previous prescribing regulations for the medication mifepristone, effectively terminating the telemedicine and mail-order access established under the current administration.

聯邦上訴法院要求 Mifepristone 藥物必須恢復之前的處方規定，實際上終止了現任政府建立的遠端醫療與郵購獲取渠道。

The judicial order necessitates a transition from the relaxed Food and Drug Administration (FDA) guidelines—which permitted remote prescriptions and home delivery—back to a requirement for in-person clinical consultations. This mandate applies nationwide, significantly restricting access to the standard two-drug regimen consisting of mifepristone and misoprostol. In response, pharmaceutical entities Danco Laboratories and GenBioPro have petitioned the Supreme Court for an expedited restoration of the Biden-era rules, citing the immediate curtailment of access, particularly within jurisdictions where abortion is prohibited.

法院指令要求從較寬鬆的美國食品藥品監督管理局 (FDA) 指引——即允許遠端處方與宅配服務——恢復至要求親自進行臨床諮詢。此指令適用於全國，顯著限制了獲取由 mifepristone 與 misoprostol 組成的標準雙藥療法的機會。對此，製藥公司 Danco Laboratories 與 GenBioPro 已向最高法院請願，要求加速恢復拜登時期的規則，理由是獲取渠道立即被削減，尤其是在禁止墮胎的司法管轄區內。

In the absence of mifepristone, clinical practitioners may utilize a misoprostol-only protocol. While the American College of Obstetricians and Gynecologists and the World Health Organization characterize this single-drug regimen as a safe and effective alternative, it is associated with a higher incidence of adverse effects, including nausea, vomiting, and prolonged cramping. The misoprostol-only process is temporally more compressed, concluding within 9 to 12 hours, whereas the combined regimen requires approximately 30 hours. Furthermore, while the combined protocol is FDA-approved up to 10 weeks of gestation, some data suggest misoprostol-only efficacy up to 22 weeks, although procedural interventions remain the clinical preference for second-trimester terminations in permissible jurisdictions.

在缺乏 mifepristone 的情況下，臨床從業人員可採取單用 misoprostol 的方案。雖然美國產科與婦產科醫學院以及世界衛生組織將這種單藥療法定義為安全且有效的替代方案，但其伴隨的副作用發生率較高，包括噁心、嘔吐及長時間腹絞痛。單用 misoprostol 的過程在時間上較為緊湊，在 9 到 12 小時內結束，而結合療法則需要約 30 小時。此外，雖然結合療法獲得 FDA 批准用於妊娠 10 週內，但部分數據顯示單用 misoprostol 的療效可達 22 週，儘管在允許墮胎的地區，第二三個月的妊娠終止仍以手術介入為臨床首選。

Stakeholder positioning varies by institutional capacity. Some providers have indicated a readiness to pivot exclusively to misoprostol-only protocols to maintain service continuity. Conversely, certain international entities, such as the Netherlands-based Aid Access, continue to distribute both medications to patients in restrictive states, bypassing FDA regulatory oversight. Support infrastructure, including the Miscarriage and Abortion Hotline, continues to provide clinical consultations regardless of the legality of the medication's acquisition within a specific state.

利害關係人的立場依據機構能力而異。部分提供者表示已準備完全轉向單用 misoprostol 方案以維持服務連續性。相反，某些國際實體（如總部位於荷蘭的 Aid Access）繼續向限制較多的州份患者分發兩種藥物，以此繞過 FDA 的監管。包括 Miscarriage and Abortion Hotline 在內的支援基礎設施，無論藥物獲取在特定州份是否合法，仍將繼續提供臨床諮詢。

The current landscape is characterized by a legal transition toward in-person prescribing requirements, pending a potential Supreme Court intervention regarding mail-order access.

目前的局面是以法律過渡至要求親自處方為主，並待最高法院針對郵購獲取渠道可能採取的干預措施。